{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"98.1","upperLimit":"99.2","value":"98.8"},{"groupId":"OG001","lowerLimit":"96.2","upperLimit":"97.4","value":"96.9"},{"groupId":"OG002","lowerLimit":"96.3","upperLimit":"97.6","value":"97.0"},{"groupId":"OG003","lowerLimit":"89.1","upperLimit":"92.5","value":"91.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1619"},{"groupId":"OG001","value":"3399"},{"groupId":"OG002","value":"3312"},{"groupId":"OG003","value":"1389"}],"units":"Participants"}],"description":"Recurrence-free interval (RFS) is defined as time from date of randomization or registration to the date of first recurrence of breast cancer (ipsilateral breast tumor recurrence, local/regional recurrence, distant recurrence) or to the date of death with recurrence, if death is the first manifestation of recurrence. The distribution of RFS (eg, 5-year RFS rate) is estimated using Kaplan-Meier method.","dispersionType":"95% Confidence Interval","groups":[{"description":"Group 1 (Oncotype DX recurrence score =\\< 10): Patients in this group receive hormone therapy with tamoxifen, anastrozole, letrozole, or exemestane PO for up to 5 years. Some patients then continue to receive hormone therapy for an additional 5 years.\n\nAnastrozole: Given PO Exemestane: Given PO Letrozole: Given PO Tamoxifen: Given PO","id":"OG000","title":"Arm A"},{"description":"Group 2 (Oncotype DX recurrence score 11-25): Patients receive hormone therapy with tamoxifen, anastrozole, letrozole, or exemestane PO for up to 5 years. Some patients then continue to receive hormone therapy for an additional 5 years.\n\nAnastrozole: Given PO Exemestane: Given PO Letrozole: Given PO Tamoxifen: Given PO","id":"OG001","title":"Arm B"},{"description":"Group 2 (Oncotype DX recurrence score 11-25): Patients receive standard combination chemotherapy at the discretion of the treating physician. Within 4 weeks after the last dose of chemotherapy, patients receive hormonal therapy as in Group 1 at the discretion of the treating physician.\n\nAnastrozole: Given PO Exemestane: Given PO Letrozole: Given PO Tamoxifen: Given PO\n\nCombination chemotherapy: including oral CMF, IV CMF, standard AC, dose dense AC, standard AC-T, dose dense AC-T, FEC, TAC, TC, other protocol-specified regimens if participating in other CTSU trials including chemotherapy, and other regimens not protocol-specified if not participating in CTSU trials","id":"OG002","title":"Arm C"},{"description":"Group 3 (Oncotype DX recurrence score \\>= 26): Patients in this group receive combination chemotherapy followed by hormone therapy similar to the patients in Group 2 who are assigned to receive both types of treatment.\n\nAnastrozole: Given PO Exemestane: Given PO Letrozole: Given PO Tamoxifen: Given PO\n\nCombination chemotherapy: including oral CMF, IV CMF, standard AC, dose dense AC, standard AC-T, dose dense AC-T, FEC, TAC, TC, other protocol-specified regimens if participating in other CTSU trials including chemotherapy, and other regimens not protocol-specified if not participating in CTSU trials","id":"OG003","title":"Arm D"}],"paramType":"NUMBER","populationDescription":"All eligible patients who had on-study data and follow-up data were included in the analysis","reportingStatus":"POSTED","timeFrame":"Assessed every 6 months within 5 years from registration and then annually up to 20 years, RFS rate estimated at 5 years","title":"5-year Recurrence-free Interval","type":"SECONDARY","unitOfMeasure":"percentage of participants"}